




APL-143

Product number A88143

APL-143 is a next-generation ionizable lipid designed for use in LNP (lipid nanoparticle) formulations. Engineered for mRNA and saRNA therapeutics and vaccines, APL-143 delivers excellent transfection efficiency across a diverse range of cell types, including muscle cells, macrophages, and dendritic cell models. Formulations using this lipid demonstrate enhanced transfection in vaccine-relevant models compared to benchmark formulations under the same conditions. Furthermore, its performance is highly tunable through strategic helper-lipid and sterol selection, supporting its versatility as a prime candidate for RNA vaccine development. Ultimately, APL-143 provides an alternative, high-performance solution capable of driving high antigen expression for next-generation therapeutics.

Key product features include:

- Superior transfection and translation across multiple cell types
- Highly tunable immune profiles using different helper lipids or sterols
- Generates robust antigen-specific immune responses in saRNA formulations
- Alternative solution to current commercial benchmarks with higher versatility
- Compatible with standard microfluidic LNP preparation workflows



Product information

Physical and Chemical Properties

CAS Number 3056013-61-4

Molecular Weight 895.36

Purity and Material Grade >99%, Research-Use-Only, not intended for use in humans

Storage Temperature -20 °C, not light sensitive, not hygroscopic

Application RNA-LNP formulation development; mRNA/saRNA vaccine research

¹CAS is a registered trademark of the American Chemical Society

Non-warranty

The information in this publication is believed to be accurate and is given in good faith, but no representation or warranty as to its completeness or accuracy is made. Suggestions for uses or applications are only opinions. Users are responsible for determining the suitability of these products for their own particular purpose. No representation or warranty, expressed or implied, is made with respect to information or products including, without limitation, warranties of merchantability, fitness for a particular purpose, non-infringement of any third-party patent or other intellectual property rights including, without limit, copyright, trademark and designs. Unless otherwise stated, any trademarks identified herein are trademarks of the Croda group of companies.

05/26 CPD083v1 EN

APL-143

Product number A88143

Figure 1
Common Formulation Composition (mol %)




Figure 2
In Vitro Macrophage Transfection Efficiency




Figure 3
Avian flu saRNA-LNP study of immunogenicity (hemagglutination inhibition geometric mean)




Figure 4
Transfection Efficiency




Table 1

Physicochemical Attributes	
Size	~95-100 nm
Polydispersity	< 0.15
Zeta potential	pH 7.5 = -10 pH 5.5 = 24
Encapsulation Efficiency	> 99%

*All formulations prepared with ionizable lipid, DSPC, Cholesterol and DMG-PEG (molar ratio of 50:10:38.5:1.5)

Did you know that Avanti Research also offers formulations services?

Not sure how to formulate with APL-143?

Want to perform feasibility studies without equipment investment?

Our Formulations experts are ready to help you translate your product ideas into reality. We offer support and guidance from initial concept to full-scale production!

Non-warranty

The information in this publication is believed to be accurate and is given in good faith, but no representation or warranty as to its completeness or accuracy is made. Suggestions for uses or applications are only opinions. Users are responsible for determining the suitability of these products for their own particular purpose. No representation or warranty, expressed or implied, is made with respect to information or products including, without limitation, warranties of merchantability, fitness for a particular purpose, non-infringement of any third-party patent or other intellectual property rights including, without limit, copyright, trademark and designs. Unless otherwise stated, any trademarks identified herein are trademarks of the Croda group of companies.

©2026 Croda International.

05/26 CPDS083v1 EN